Do you want to read an article? Please log in or register.
Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis
Interstitial Lung Disease
Related content
RECOMMENDED
Interstitial Lung Disease
Predictors of progression in systemic sclerosis patients with interstitial lung disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J.
Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Distler JHW, Hoffmann-Vold AM, Johnson SR, Müller Ladner U, Smith V, Volkmann ER, Maher TM
doi: 10.1183/13993003.02026-2019.
RECOMMENDED
Interstitial Lung DiseasePneumonia
[New developments in systemic sclerosis-associated interstitial lung disease]
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Rev Med Suisse
Humair G, Daccord C, Beigelman-Aubry C, Lazor R
CoughInterstitial Lung Disease
Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases
Respirology.
Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ
doi: 10.1111/resp.13084.
RECOMMENDED
Interstitial Lung Disease
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
N Engl J Med.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, SENSCIS Trial Investigators.
doi: 10.1056/NEJMoa1903076.
RECOMMENDED
Interstitial Lung Disease
Predicting outcomes in rheumatoid arthritis related interstitial lung disease
Eur Respir J.
Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU
doi: 10.1183/13993003.00869-2018.
RECOMMENDED
Interstitial Lung Disease
Systemic sclerosis-associated interstitial lung disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Perelas A, Silver RM, Arrossi AV, Highland KB
doi: 10.1016/S2213-2600(19)30480-1.
RECOMMENDED
Interstitial Lung Disease
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ann Rheum Dis.
Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators
doi: 10.1136/annrheumdis-2020-217331.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
doi: 10.1016/S2213-2600(20)30036-9.
Interstitial Lung Disease
Telomere Length and Genetic Variant Associations with Interstitial Lung Disease Progression and Survival
Eur Respir J.
Newton CA, Oldham JM, Ley B, Anand V, Adegunsoye A, Liu G, Batra K, Torrealba J, Kozlitina J, Glazer C, Strek ME5, Wolters PJ, Noth I, Garcia CK
doi: 10.1183/13993003.